Cipla has entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences (Inzpera). The company will pay a consideration of around Rs 110.65 crore for acquisition of equity shares and non-convertible redeemable preference shares, representing 100% of Inzpera’s shareholding.
Upon acquisition, Inzpera will become wholly owned subsidiary of the company. The acquisition is a strategic move aimed at combining Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with the company’s strong distribution network and operational capabilities to drive growth and scalability.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.90 |
| Dr. Reddys Lab | 1234.40 |
| Cipla | 1232.35 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2328.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: